AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02171182
Drug: Qutenza
RxNorm normalized name: Qutenza
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsaicin patch
Trial: NCT03525392
Drug: 177Lu-3BP-227 (also called 177Lu-IPN01087)
RxNorm normalized name: 177Lu-dotatate
DrugBank: Zalsenertant tetraxetan lutetium Lu-177 (DB17327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The cumulative activity of the treatment investigational medicinal product (IMP) formulation will be administered in two intravenous (i.v.) infusions separated by at least 4 weeks (28 days). Up to 6 administrations can be given (2 cycles plus 4 optional additional)
Trial: NCT01834170
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two intratumoral injections of gemcitabine under endoscopic ultrasound (EUS)-guidance at month 0 and month 3.~The patients will receive systemic chemotherapy with or without radiotherapy at the discretion of oncologist
Trial: NCT03750786
Drug: Arfolitixorin
RxNorm normalized name: Folitixorin
DrugBank: Folitixorin (DB17113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 5 mg/kg intravenous infusion; Oxaliplatin 85 mg/m2 intravenous infusion; 5-FU 400 mg/m2 intravenous bolus; Arfolitixorin 60 mg/m2 intravenous bolus; 5-FU 2400 mg/m2 intravenous infusion; Arfolitixorin 60 mg/m2 intravenous bolus
Trial: NCT01349660
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 10 mg/kg IV every 2 weeks
Trial: NCT00939562
Drug: doxycycline monohydrate tablet
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, 100 mg, Single dose
Trial: NCT00488215
Drug: prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The dose will be consecutively escalated in 2 mg steps per day, starting from 2 mg up to 20 mg once daily or until severe drug-related adverse events occur (= individual maximum tolerable dose, on decision of the subject and/or investigator).
Trial: NCT00506441
Drug: MCI-196
RxNorm normalized name: kaolin 196 MG/ML
DrugBank: Kaolin (DB01575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose (Open-label) and 4 weeks of double blind
Trial: NCT05236907
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7.5 mg of Midazolam orally.
Trial: NCT00612560
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg per day
Trial: NCT03541200
Drug: MT-8554
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT-8554 Oral
Trial: NCT00335933
Drug: Gabapentin extended-release tablets
RxNorm normalized name: gabapentin Extended Release Oral Tablet
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02104778
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In dexamethasone group, dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
Trial: NCT04445987
Drug: ARQ-154
RxNorm normalized name: ARQ 092
DrugBank: Miransertib (DB14982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ-154 foam 0.3% applied once daily for 52 weeks
Trial: NCT02044419
Drug: lomitapide
RxNorm normalized name: Lomitapide
DrugBank: Lomitapide (DB08827)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03585803
Drug: KMRC011 5μg or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intramuscular Injection of KMRC011 5μg or Placebo(Normal Saline) 0.1ml
Trial: NCT03585803
Drug: KMRC011 10μg or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intramuscular Injection of KMRC011 10μg or Placebo(Normal Saline) 0.2ml
Trial: NCT03585803
Drug: KMRC011 15μg or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intramuscular Injection of KMRC011 15μg or Placebo(Normal Saline) 0.3ml
Trial: NCT03585803
Drug: KMRC011 20μg or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intramuscular Injection of KMRC011 30μg or Placebo(Normal Saline) 0.4ml
Trial: NCT01082146
Drug: Lurasidone
RxNorm normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg suspension, PO, for 7 days
Trial: NCT03585803
Drug: KMRC011 25μg or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intramuscular Injection of KMRC011 45μg or Placebo(Normal Saline) 0.5ml
Trial: NCT00970762
Drug: Rocuronium 0.6 mg/kg intubating dose
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg intubating dose
Trial: NCT00970762
Drug: Rocuronium 0.9 mg/kg intubating dose
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.9 mg/kg intubating dose of rocuronium
Trial: NCT00970762
Drug: Rocuronium 0.1 mg/kg maintenance dose
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.1 mg/kg maintenance dose following the intubating dose.
Trial: NCT00970762
Drug: Rocuronium 0.15 mg/kg maintenance dose
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.15 mg/kg maintenance dose following the intubating dose
Trial: NCT00970762
Drug: Rocuronium 0.2 mg/kg maintenance
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.2 mg/kg maintenance dose following the intubating dose
Trial: NCT00970762
Drug: Vecuronium 0.1 mg/kg intubating dose
DrugBank: Vecuronium (DB01339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.1 mg/kg intubating dose
Trial: NCT00970762
Drug: Vecuronium 0.025 mg/kg maintenance dose
DrugBank: Vecuronium (DB01339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.025 mg/kg maintenance dose following the intubating dose
Trial: NCT01159639
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: patients with inappropriate response to aspirin 300 mg after CABG, assessed by multiple electrode aggregometry are randomized to receive clopidogrel 75 mg daily dose
Trial: NCT03958630
Drug: 11C-ER176
RxNorm normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET biomarker for inflammation
Trial: NCT03958630
Drug: 11C-PIB
RxNorm normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET biomarker for amyloid
Trial: NCT00222872
Drug: Parathyroid Hormone-related Protein
RxNorm normalized name: Parathyroid Hormone-Related Protein 1-36
DrugBank: Parathyroid Hormone-Related Protein 1-36 (DB16278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTHrP(1-36) starting at 500 micrograms, then increasing by 125 micrograms up to a maximum of 1,500 micrograms.
Trial: NCT00330148
Drug: melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d
DrugBank: Nifurtimox (DB11820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03170817
Drug: N-13 ammonia
DrugBank: Ammonia (DB11118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-10 mCi intravenous injection of N-13 ammonia radiopharmaceutical at rest and at stress
Trial: NCT03170817
Drug: Regadenoson
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4 mg/5mL intravenous injection to induce pharmacologic stress (Astellas Pharma US, Inc.)
Trial: NCT00242411
Drug: Budesonide/Formoterol Turbuhaler
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00045773
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 - 200mg, once per day for 12 weeks.
Trial: NCT02729064
Drug: Humulin R
RxNorm normalized name: HumuLIN R
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study subjects will receive intranasal insulin (Humulin R) via a metered nasal dispenser.
Trial: NCT01815736
Drug: ATV
RxNorm normalized name: PrenatVite Tablet
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg capsule administered orally once daily
Trial: NCT01815736
Drug: COBI
RxNorm normalized name: Ricobid H
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150 mg tablet administered orally once daily
Trial: NCT03656393
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg, orally, every day) for 56 days
Trial: NCT03656393
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine (60 mg/m2, orally, Once every three weeks) for 6 weeks
Trial: NCT01905150
Drug: G-FLIP-DM
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: G-FLIP-DM is low doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, Oxaliplatin, Docetaxel and Mitomycin C
Trial: NCT03656393
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (AUC5, intravenously drip, once a week) for 6 weeks
Trial: NCT01363570
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
Trial: NCT02114619
Drug: Low dose of I-131
RxNorm normalized name: iobenguane I-131
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We wil administer 100 micro currie of iodine per thyroid gram
Trial: NCT01602029
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
Trial: NCT00728910
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg QD for 4 weeks
Trial: NCT00728910
Drug: ER Niacin
RxNorm normalized name: Leader Niacin 500mg Tablet
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg QD added to atorvastatin and ABT335 for 10 weeks
Trial: NCT00189176
Drug: Tetrathiomolybdate
RxNorm normalized name: Tetrathiomolybdate
DrugBank: Tetrathiomolybdate (DB05088)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00518895
Drug: dacarbazine plus Genasense
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus Genasense group will receive Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the Genasense infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
Trial: NCT00518895
Drug: dacarbazine plus placebo
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus placebo group will receive placebo (that is, locally available commercial 0.9% Sodium Chloride Injection) by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the placebo infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
Trial: NCT03410004
Drug: Chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
Trial: NCT03880136
Drug: CTP-543
RxNorm normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Once daily dosing
Trial: NCT01737307
Drug: Fluoride varnish
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride Varnish (NaF 5%)
Trial: NCT00230334
Drug: Gleevec
RxNorm normalized name: Gleevec
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04413344
Drug: Bromocriptine
RxNorm normalized name: Bromocriptine
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TW-012R: Each tablet contains 2.87 mg of bromocriptine mesilate (JP) (2.5 mg of bromocriptine)
Trial: NCT00019461
Drug: carboxyamidotriazole
RxNorm normalized name: Carboxyamidotriazole
DrugBank: Carboxyamidotriazole (DB11960)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02076386
Drug: Dolutegravir
RxNorm normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
Trial: NCT02651870
Drug: Candesartan 16mg
RxNorm normalized name: CANDESARTAN 16MG/HCTZ 12.5MG TAB
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02651870
Drug: Amlodipine 5mg
RxNorm normalized name: LEVAMLODIPINE 5MG TAB
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02651870
Drug: Amlodipine 10mg
RxNorm normalized name: AMLODIPINE 10MG/VALSARTAN 160MG TAB
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00646399
Drug: Pagibaximab 50 mg/mL
DrugBank: Pagibaximab (DB17786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pagibaximab 100 mg/kg dosed on Days 0, 1, 2, 9, 16 and 23
Trial: NCT01149720
Drug: Tivantinib (ARQ 197) Capsule
RxNorm normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral BID 360 mg dose (Capsule C: 6 X 60 mg) of ARQ 197 at least 1 hour before or 2 hours after a meal for 7 days
Trial: NCT02314481
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film coated tablet
Trial: NCT02314481
Drug: Alectinib
RxNorm normalized name: Alectinib
DrugBank: Alectinib (DB11363)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: capsule
Trial: NCT02314481
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Powder for concentrate for solution for infusion
Trial: NCT01051557
Drug: Perifosine
RxNorm normalized name: Perifosine
DrugBank: Perifosine (DB06641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01051557
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT02392026
Drug: Metronidazole Gel
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole Vaginal Gel 1.3% administered via applicator
Trial: NCT00613821
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
Trial: NCT00613821
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
Trial: NCT00137345
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00166868
Drug: Lactobacillus casei rhamnosus (Lcr35)
RxNorm normalized name: Lactobacillus casei rhamnosus
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00166868
Drug: Neomycin
RxNorm normalized name: Neomycin
DrugBank: Neomycin (DB00994)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02553642
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monotherapy Treatment - Nivolumab 240 mg flat dose Dosed q 2 weeks~OR~- Nivolumab 480 mg flat dose Dosed q 4 weeks~for up to 2 years from 1st dose of nivolumab or until loss of clinical benefit
Trial: NCT02553642
Drug: Nivolumab plus Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination Treatment~* Ipilimumab 3 mg/kg~* Nivolumab 1 mg/kg Dosed q 3 weeks x 4 doses
Trial: NCT04069221
Drug: Single oral dose of 400 mg OZ439
RxNorm normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of 400 mg OZ439
Trial: NCT04069221
Drug: Single oral dose of cobicistat
RxNorm normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single oral dose of 150 mg cobicistat
Trial: NCT04005729
Drug: Cangrelor 50 MG
RxNorm normalized name: cangrelor 50 MG
DrugBank: Cangrelor (DB06441)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 30 mcg/kg bolus, then 4h infusion 4 mcg/kg/min
Trial: NCT01736943
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib will be given twice a week subcutaneously (under the skin) for two weeks in every 3 week cycle.
Trial: NCT01736943
Drug: Doxil
RxNorm normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxil or LipoDox will also be given through a venous catheter (inside your vein). Doxil or LipoDox will be given over 60 to 90 minutes on Day 4 of every 21-day cycle.
Trial: NCT01431495
Drug: Pidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pidogrel(R)75 mg/day for period ranging from 1 to 6 months.
Trial: NCT01018758
Drug: Palonosetron
RxNorm normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palonosetron will be given as an intravenous bolus at the dose of 250 micrograms over 30 seconds beginning 30 minutes before chemotherapy.
Trial: NCT01589367
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin HCl 500mg(morning/evening) PO daily x 1week Metformin HCl 1000mg(morning)and 500mg(evening)PO daily x 1week Metformin HCl 1000mg(morning/evening) PO daily x 22weeks
Trial: NCT01149720
Drug: Tivantinib (ARQ 197) Tablet
RxNorm normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral BID 360 mg dose (Tablet: 3 x 120 mg) of ARQ 197 under fed conditions for 7 days
Trial: NCT01431495
Drug: Plavix
RxNorm normalized name: Plavix
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Plavix(R) 75 mg/day for period ranging from 1 to 6 months.
Trial: NCT01932697
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00084344
Drug: 4-hydroxytamoxifen
RxNorm normalized name: 4-hydroxytamoxifen
DrugBank: Afimoxifene (DB04468)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01852318
Drug: pregabalin 75mg daily for 12 weeks
RxNorm normalized name: pregabalin 75 MG
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral pregabalin 75mg daily for 12 weeks
Trial: NCT01852318
Drug: fexofenadine 60 mg daily for 12 weeks
RxNorm normalized name: fexofenadine hydrochloride 60 MG
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fexofenadine 60 mg daily for 12 weeks
Trial: NCT01882543
Drug: AQX-1125
RxNorm normalized name: AQX-1125
DrugBank: AQX-1125 (DB13012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic SHIP1 activator
Trial: NCT03788603
Drug: Rogaratinib (BAY1163877)
RxNorm normalized name: Rogaratinib
DrugBank: Rogaratinib (DB15078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rogaratinib will be administered on 20 days in Cycle 1 (single dosing on Day 1 and twice daily dosing on Days 3-21). In Cycles ≥2, rogaratinib will be administered twice daily for 21 days, with cycles repeated every 21 days. Treatment will be continued until death, tumor progression, unacceptable toxicity, consent withdrawal, or until another criterion is met for withdrawal from the study at the discretion of the investigator.
Trial: NCT01149720
Drug: Tivantinib (ARQ 197) Capsule D, oral
DrugBank: Tivantinib (DB12200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral BID 360 mg dose (Capsule D: 3 x 120 mg) of ARQ 197 under fed conditions in the extension phase
Trial: NCT01398501
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, 200 to 400 mg QD or BID